Timber Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. (ticker: TMBR) was a U.S.-based biopharmaceutical company listed on NASDAQ in the United States. The company was focused on rare and orphan dermatologic diseases, with an R&D strategy built around non-systemic or locally delivered therapies for highly underserved skin conditions. Its core historical focus was congenital ichthyosis (CI), including X-linked recessive ichthyosis (XLRI) and autosomal recessive congenital ichthyosis (ARCI), as well as other sclerotic skin disorders. Timber’s current corporate identity emerged after a business combination with BioPharmX that closed in May 2020, after which the company concentrated its development efforts on rare dermatology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1504167/000155837023005284/tmbr-20221231x10k.htm)) The lead and most advanced asset was TMB-001, a patented topical isotretinoin formulation using Timber’s proprietary delivery system. The rationale was to target the diseased skin while minimizing systemic exposure. Timber reported positive phase 2b results, including clinically meaningful improvements in disease severity and a generally favorable safety profile. Following an end-of-phase-2 meeting with the FDA, the company advanced TMB-001 into a pivotal phase 3 ASCEND study, while also securing orphan, fast-track, and breakthrough-related regulatory milestones in selected CI populations. Timber also maintained an earlier-stage program, TMB-003, a locally applied formulation of sitaxsentan for sclerotic skin diseases, which remained preclinical. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1504167/000155837023005284/tmbr-20221231x10k.htm)) From a competitive standpoint, Timber operated in a narrow niche with limited approved treatment options in the United States for these rare ichthyosis subtypes. That scarcity supported the investment thesis, but it also meant heavy dependence on a small number of pipeline assets and on clinical/regulatory execution. The company differentiated itself through a rare-disease dermatology focus, the use of established mechanisms of action, and an effort to develop therapies that could reduce systemic risk. Its geographic footprint was primarily U.S.-centered, with historic offices in Basking Ridge, New Jersey. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1504167/000155837023005284/tmbr-20221231x10k.htm)) A key recent development was the January 2024 completion of LEO Pharma’s acquisition of Timber’s key assets, including TMB-001, following Timber’s Chapter 11 process and asset sale. For investors, that is important context: Timber was no longer operating as a conventional independent development-stage biotech after that transaction, and its value proposition shifted from standalone pipeline optionality to a realized strategic sale. In market terms, TMBR is best understood as a U.S. NASDAQ biotech story with a rare-disease dermatology pipeline, high scientific optionality, and the binary risk profile typical of small-cap specialty pharma. ([businesswire.com](https://www.businesswire.com/news/home/20240123892208/en/LEO-Pharma-Finalizes-Acquisition-of-Key-Assets-From-Timber-Pharmaceuticals?utm_source=openai))